Vivani Medical completes dosing in SLIM-1 Phase 1 trial of NPM-139 semaglutide implant for weight management
VANI•Trial design and next steps
The trial is designed to assess safety, tolerability, and drug exposure, with a Wegovy injection group included for comparison.
The program targets less frequent dosing to support adherence, with an implant designed for reversibility if treatment must be stopped.
Management expects the Phase 1 readout to support a Phase 2 dose-ranging trial start in 2027.
SLIM-1 Phase 1 dosing completed
Vivani Medical completed enrollment and initial dosing in SLIM-1, a Phase 1 study of NPM-139, a long-acting semaglutide implant for chronic weight management.
Results have not been presented; top-line data from the 20-participant trial is expected in November 2026.
